A new study in Nature reports that semaglutide, a glucagon-like peptide-1 receptor agonist, improved several measures of physiological ageing and extended lifespan when treatment was started late in life in older female mice.
The finding is scientifically interesting because it suggests that some effects of GLP-1 receptor activation may overlap with — and in some measures go beyond — the effects of calorie restriction. It does not show that semaglutide slows ageing or extends life in humans.
What the researchers did
The researchers studied 20-month-old female C57BL/6 mice, an age intended to model late-life intervention rather than lifelong treatment.
Some mice received semaglutide. For lifespan analysis, treatment continued until death. Other experiments assessed physiological, cellular and molecular effects after several months of treatment.
The study also included a calorie-restriction comparison. Because semaglutide reduced food intake, the researchers matched another group's calorie intake to help separate effects associated with eating less from effects that might be attributable to GLP-1 receptor activation itself.
What they found
Semaglutide-treated mice showed improvements across several functional measures and attenuation of multiple biological features associated with ageing, including inflammation, cellular senescence, mitochondrial dysfunction, genomic instability, loss of proteostasis and stem-cell attrition.
The researchers also reported an extension of lifespan in the treated group.
Semaglutide reduced food intake by about 24%, so calorie reduction clearly forms part of the biological context. However, the drug-treated mice performed better than the matched calorie-restricted group on some measures, including exploratory behaviour, spatial memory and glucose control.
This led the authors to describe GLP-1 receptor activation as having features of a calorie-restriction mimetic — an intervention that reproduces some biological effects of calorie restriction without being identical to it.
Why the calorie-restriction comparison matters
Calorie restriction has extended lifespan in several laboratory species. If a drug causes animals to eat less, longer survival could simply reflect reduced calorie intake rather than a separate drug effect.
The matched comparison was therefore central to the study design.
The study found substantial overlap between semaglutide and calorie restriction, but also differences. That makes the result more biologically interesting, while still leaving the precise mechanisms unresolved.
What this does not mean
This was not a human longevity trial.
The experiment used one inbred mouse strain and only female animals. Laboratory mice live in highly controlled environments and differ substantially from humans in lifespan, metabolism, disease patterns and exposure to competing risks.
A treatment that extends median or overall survival in mice can fail to do so in humans even when the underlying mechanism appears plausible.
The authors explicitly state that determining whether GLP-1 receptor activation alters ageing trajectories or lifespan in humans would require long-term clinical studies designed to assess ageing-related outcomes.
Why the result still matters
GLP-1 medicines are already widely used in humans for established indications including type 2 diabetes and obesity, and clinical trials have documented benefits in several cardiometabolic outcomes.
That makes a mechanistic ageing study more relevant than an experiment involving a molecule with no human exposure history. But prior clinical use does not convert an animal ageing result into a new indication.
The useful scientific question is whether pathways already influenced by GLP-1 medicines — appetite, glucose regulation, inflammation, nutrient sensing and possibly neural function — intersect with mechanisms that shape age-related decline.
This study provides evidence that they do in older female mice. It does not yet answer whether the same biology can be translated into longer or healthier human life.
What to watch next
The strongest next evidence would come from independent replication in additional mouse strains and both sexes, followed by human studies examining clinically meaningful ageing-related outcomes rather than short-term biomarkers alone.
Until then, the appropriate interpretation is narrow: semaglutide produced a broad anti-ageing phenotype and extended lifespan in this particular mouse model.
Primary source
- Feng Y, Barthez M, Wang Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. Published 2 September 2026. DOI: 10.1038/s41586-026-10940-7. https://www.nature.com/articles/s41586-026-10940-7